-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, China has continuously introduced policies to help the development of the traditional Chinese medicine industry, and the entire industry has ushered in a period of vigorous developme.
At present, the development of the traditional Chinese medicine industry has risen to the national strategic lev.
The "14th Five-Year Plan for the Development of Traditional Chinese Medicine" proposes that by 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, and the high-quality development policy and system of traditional Chinese medicine will be further improv.
The revitalization and development of medicine has achieved positive results, and its unique advantages in the construction of a healthy China have been brought into full pl.
The industry believes that under the background of the vigorous development of traditional Chinese medicine, the top enterprises above designated size with relevant advantages will be strong, the industry concentration will increase, and the small-scale enterprises will decrea.
At present, there are about 71 A-share Chinese medicine compani.
As of April 30, these 71 Chinese medicine companies have disclosed their annual repor.
In 2021, they will achieve a total operating income of 335 billion yuan and a net profit of 37 billion yu.
Among them, more than half of the companies announced the good news, reaching 47, including Datang Pharmaceutical, Tongrentang, Baiyunshan, Kunyao,e.
Among the above-mentioned companies that announced the good news, many companies have doubled their net profit, including Dong'e Ejiao, Kangenbei, *ST Kangmei, Jianmin Group and Tas.
Among them, Dong E E Jiao will obtain a net profit of 440 million in 2021, a year-on-year increase of 914
Followed by Conba, the net profit for the year was 009 billion yuan, a year-on-year increase of 34
It is worth mentioning that in terms of sub-sectors, the innovative Chinese medicine sector performed particularly we.
Among them, pharmaceutical companies including Kangenbei, Tasly, Zhongsheng Pharmaceutical, Zuoli Pharmaceutical, Teyi Pharmaceutical, e.
, will increase their net profit by more than 100% in 202The performance growth of these companies is mainly related to factors such as policy support and medical insuran.
For example, Teyi Pharmaceutical stated that under the background that the current national industrial policy strongly supports the development of the Chinese medicine industry, the company focuses on the development of Chinese patent medicine varieties, and increases the market cultivation of potential Chinese patent medicine products while expanding the core produc.
and development effor.
Zuoli Pharmaceutical stated that, during the reporting period, based on the advantages of the three core products of Wuling Capsule, Bailing Tablet and Lingze Tablet being included in the National Essential Drug List, it adhered to the principle of "stable self-operation, strong investment promotion, cloth retail, and full module.
Marketing strategy, continuous increase in market investment and development coverage of terminal medical institutions, all three have achieved rapid growth in operating inco.
Based on the general trend of innovative development of traditional Chinese medicine, many companies have also strengthened their determination to increase investment in innovative R&.
For example, Guangzhou Baiyunshan has continued to promote the layout of innovative drugs in recent years, increasing R&D investment year by ye.
The financial report shows that in 2021, the research and development expenses of Guangzhou Baiyunshan will be 875 million yuan, a year-on-year increase of 49
For another example, Kangyuan Pharmaceutical mentioned in its 2021 annual report that in terms of new Chinese medicines under research, in 2022, it will accelerate the establishment and research and development of medicines for pediatrics, cardiovascular, geriatrics and metabolic diseases, expand new clinical fields, and adjust clinical advanceme.
strategy to form a continuous output capability for the production of new dru.
In addition, judging from the stock prices of these 71 traditional Chinese medicine companies, many companies have achieved significant growth in the past two yea.
From the beginning of the year to 2021, the growth rate of over 100%, such as Essence Pharma, Guangyuyuan, Dali Pharma, Panlong Pharma, Tongrentang, China Resources Sanjiu, e.
, among which Essence Pharma is the top gainer, from January 4, 2021 to May 2022 On the 10th, the stock has risen by more than 500%, followed by Guangyuyuan and Dali Pharmaceutical, both of which have risen by more than 25
According to the industry, the development of the traditional Chinese medicine industry is relatively optimistic at prese.
With the development of the aging population, the growth of chronic disease rates, the support of favorable national policies, and the promotion of internationalization, the traditional Chinese medicine industry has a huge room for growth in the futu.
A highly profitable Chinese medicine head enterpri.
At present, the development of the traditional Chinese medicine industry has risen to the national strategic lev.
The "14th Five-Year Plan for the Development of Traditional Chinese Medicine" proposes that by 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, and the high-quality development policy and system of traditional Chinese medicine will be further improv.
The revitalization and development of medicine has achieved positive results, and its unique advantages in the construction of a healthy China have been brought into full pl.
The industry believes that under the background of the vigorous development of traditional Chinese medicine, the top enterprises above designated size with relevant advantages will be strong, the industry concentration will increase, and the small-scale enterprises will decrea.
At present, there are about 71 A-share Chinese medicine compani.
As of April 30, these 71 Chinese medicine companies have disclosed their annual repor.
In 2021, they will achieve a total operating income of 335 billion yuan and a net profit of 37 billion yu.
Among them, more than half of the companies announced the good news, reaching 47, including Datang Pharmaceutical, Tongrentang, Baiyunshan, Kunyao,e.
Among the above-mentioned companies that announced the good news, many companies have doubled their net profit, including Dong'e Ejiao, Kangenbei, *ST Kangmei, Jianmin Group and Tas.
Among them, Dong E E Jiao will obtain a net profit of 440 million in 2021, a year-on-year increase of 914
Followed by Conba, the net profit for the year was 009 billion yuan, a year-on-year increase of 34
It is worth mentioning that in terms of sub-sectors, the innovative Chinese medicine sector performed particularly we.
Among them, pharmaceutical companies including Kangenbei, Tasly, Zhongsheng Pharmaceutical, Zuoli Pharmaceutical, Teyi Pharmaceutical, e.
, will increase their net profit by more than 100% in 202The performance growth of these companies is mainly related to factors such as policy support and medical insuran.
For example, Teyi Pharmaceutical stated that under the background that the current national industrial policy strongly supports the development of the Chinese medicine industry, the company focuses on the development of Chinese patent medicine varieties, and increases the market cultivation of potential Chinese patent medicine products while expanding the core produc.
and development effor.
Zuoli Pharmaceutical stated that, during the reporting period, based on the advantages of the three core products of Wuling Capsule, Bailing Tablet and Lingze Tablet being included in the National Essential Drug List, it adhered to the principle of "stable self-operation, strong investment promotion, cloth retail, and full module.
Marketing strategy, continuous increase in market investment and development coverage of terminal medical institutions, all three have achieved rapid growth in operating inco.
Based on the general trend of innovative development of traditional Chinese medicine, many companies have also strengthened their determination to increase investment in innovative R&.
For example, Guangzhou Baiyunshan has continued to promote the layout of innovative drugs in recent years, increasing R&D investment year by ye.
The financial report shows that in 2021, the research and development expenses of Guangzhou Baiyunshan will be 875 million yuan, a year-on-year increase of 49
For another example, Kangyuan Pharmaceutical mentioned in its 2021 annual report that in terms of new Chinese medicines under research, in 2022, it will accelerate the establishment and research and development of medicines for pediatrics, cardiovascular, geriatrics and metabolic diseases, expand new clinical fields, and adjust clinical advanceme.
strategy to form a continuous output capability for the production of new dru.
In addition, judging from the stock prices of these 71 traditional Chinese medicine companies, many companies have achieved significant growth in the past two yea.
From the beginning of the year to 2021, the growth rate of over 100%, such as Essence Pharma, Guangyuyuan, Dali Pharma, Panlong Pharma, Tongrentang, China Resources Sanjiu, e.
, among which Essence Pharma is the top gainer, from January 4, 2021 to May 2022 On the 10th, the stock has risen by more than 500%, followed by Guangyuyuan and Dali Pharmaceutical, both of which have risen by more than 25
According to the industry, the development of the traditional Chinese medicine industry is relatively optimistic at prese.
With the development of the aging population, the growth of chronic disease rates, the support of favorable national policies, and the promotion of internationalization, the traditional Chinese medicine industry has a huge room for growth in the futu.
A highly profitable Chinese medicine head enterpri.
